FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283778103> ?p ?o ?g. }

• W4283778103 endingPage "S369" @default.
• W4283778103 startingPage "S369" @default.
• W4283778103 abstract "Nanoliposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) is one of the standard treatments for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC). We have previously reported the real-world clinical data of nal-IRI+5-FU/LV in Japanese patients with PDAC (HGCSG2101). Herein we compared the efficacy and safety of nal-IRI+5-FU/LV by UGT1A1 status, wild type (WT) versus single heterozygous (SH), among the patients enrolled in the HGCSG2101. We retrospectively analyzed patients who received nal-IRI+5-FU/LV for unresectable PDAC at 10 institutions between June and December 2020. Data cutoff for this analysis was 30 June 2021. The median overall survival (OS), progression free survival (PFS) with each 95% confidence interval (CI) were estimated by the Kaplan-Meier method. Differences in the efficacy between each group were tested by means of the Log-rank test. The Cox regression analysis was used to estimate hazard ratios (HRs) of SH compared with WT with 95 % CIs. Tumor response was assessed by RECIST ver. 1.1. Adverse events were evaluated according to CTCAE ver. 5.0. Qualitative and quantitative variables were compared using the chi-square test or Fisher’s test and using a nonparametric (Wilcoxon) test, respectively. A total of 48 patients were evaluated (26 and 22 patients with UGT1A1 WT and SH, respectively). The number of patients who had their initial dose of nal-IRI reduced for any reason was 6 (23.1%) in the WT group and 10 (45.5%) in the SH group, respectively (p=0.20). The median relative dose intensity of nal-IRI was 0.79 (range, 0.43-0.99) in WT group and 0.69 (range, 0.55-0.96) in SH group, respectively (p=0.18). The median PFS was 2.8 months (95%CI: 1.9-6.9) in WT group and 2.4 months (95%CI: 1.9-6.0) in SH group, respectively (HR: 1.2, 95%CI: 0.6–2.1, p=0.63). The median OS was 6.6 months (95%CI: 4.7-11.3) in WT group and 6.8 months (95%CI: 4.3-9.4) in SH group (HR: 1.1, 95% CI: 0.5–2.1, p=0.90), respectively. The response rate was 8.0％ (95%CI: 1.7-26.1) in WT group and 16.7％ (95%CI: 5.0-40.1) in SH group (p= 0.63), respectively. Though there were no significant differences in safety between WT and SH groups, ≥grade3 neutropenia and febrile neutropenia were observed more frequently in SH group (≥grade3 neutropenia: 30.8% vs 50.0%, p=0.24, febrile neutropenia: 0.0% vs 9.1%, p=0.20, respectively). No treatment-related death was observed in each group. There was no significant difference in the treatment outcome of nal-IRI+5-FU/LV between UGT1A1 WT and SH groups. However, ≥grade3 neutropenia and febrile neutropenia tended to be more frequent in SH group despite the fact that more patients had reduced the initial dose of nal-IRI in SH group. Further analysis is needed to investigate the impact of the UGT1A1 status on the treatment outcome of nal-IRI+5-FU/LV for patients with PDAC." @default.
• W4283778103 created "2022-07-03" @default.
• W4283778103 creator A5001876291 @default.
• W4283778103 creator A5005309665 @default.
• W4283778103 creator A5007583724 @default.
• W4283778103 creator A5008729234 @default.
• W4283778103 creator A5014225991 @default.
• W4283778103 creator A5014263183 @default.
• W4283778103 creator A5023876278 @default.
• W4283778103 creator A5024713150 @default.
• W4283778103 creator A5025809883 @default.
• W4283778103 creator A5029514297 @default.
• W4283778103 creator A5029924703 @default.
• W4283778103 creator A5053092940 @default.
• W4283778103 creator A5054182211 @default.
• W4283778103 creator A5057711892 @default.
• W4283778103 creator A5060739020 @default.
• W4283778103 creator A5064137979 @default.
• W4283778103 creator A5069408787 @default.
• W4283778103 creator A5073532961 @default.
• W4283778103 creator A5077038832 @default.
• W4283778103 creator A5077794725 @default.
• W4283778103 creator A5081842907 @default.
• W4283778103 date "2022-06-01" @default.
• W4283778103 modified "2023-10-17" @default.
• W4283778103 title "SO-30 Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma" @default.
• W4283778103 doi "https://doi.org/10.1016/j.annonc.2022.04.429" @default.
• W4283778103 hasPublicationYear "2022" @default.
• W4283778103 type Work @default.
• W4283778103 citedByCount "0" @default.
• W4283778103 crossrefType "journal-article" @default.
• W4283778103 hasAuthorship W4283778103A5001876291 @default.
• W4283778103 hasAuthorship W4283778103A5005309665 @default.
• W4283778103 hasAuthorship W4283778103A5007583724 @default.
• W4283778103 hasAuthorship W4283778103A5008729234 @default.
• W4283778103 hasAuthorship W4283778103A5014225991 @default.
• W4283778103 hasAuthorship W4283778103A5014263183 @default.
• W4283778103 hasAuthorship W4283778103A5023876278 @default.
• W4283778103 hasAuthorship W4283778103A5024713150 @default.
• W4283778103 hasAuthorship W4283778103A5025809883 @default.
• W4283778103 hasAuthorship W4283778103A5029514297 @default.
• W4283778103 hasAuthorship W4283778103A5029924703 @default.
• W4283778103 hasAuthorship W4283778103A5053092940 @default.
• W4283778103 hasAuthorship W4283778103A5054182211 @default.
• W4283778103 hasAuthorship W4283778103A5057711892 @default.
• W4283778103 hasAuthorship W4283778103A5060739020 @default.
• W4283778103 hasAuthorship W4283778103A5064137979 @default.
• W4283778103 hasAuthorship W4283778103A5069408787 @default.
• W4283778103 hasAuthorship W4283778103A5073532961 @default.
• W4283778103 hasAuthorship W4283778103A5077038832 @default.
• W4283778103 hasAuthorship W4283778103A5077794725 @default.
• W4283778103 hasAuthorship W4283778103A5081842907 @default.
• W4283778103 hasBestOaLocation W42837781031 @default.
• W4283778103 hasConcept C121608353 @default.
• W4283778103 hasConcept C126322002 @default.
• W4283778103 hasConcept C143998085 @default.
• W4283778103 hasConcept C197934379 @default.
• W4283778103 hasConcept C207103383 @default.
• W4283778103 hasConcept C2776694085 @default.
• W4283778103 hasConcept C2779984678 @default.
• W4283778103 hasConcept C2780210213 @default.
• W4283778103 hasConcept C2780258809 @default.
• W4283778103 hasConcept C2780259306 @default.
• W4283778103 hasConcept C2780456651 @default.
• W4283778103 hasConcept C2781182431 @default.
• W4283778103 hasConcept C31760486 @default.
• W4283778103 hasConcept C44249647 @default.
• W4283778103 hasConcept C50382708 @default.
• W4283778103 hasConcept C526805850 @default.
• W4283778103 hasConcept C71924100 @default.
• W4283778103 hasConcept C90924648 @default.
• W4283778103 hasConceptScore W4283778103C121608353 @default.
• W4283778103 hasConceptScore W4283778103C126322002 @default.
• W4283778103 hasConceptScore W4283778103C143998085 @default.
• W4283778103 hasConceptScore W4283778103C197934379 @default.
• W4283778103 hasConceptScore W4283778103C207103383 @default.
• W4283778103 hasConceptScore W4283778103C2776694085 @default.
• W4283778103 hasConceptScore W4283778103C2779984678 @default.
• W4283778103 hasConceptScore W4283778103C2780210213 @default.
• W4283778103 hasConceptScore W4283778103C2780258809 @default.
• W4283778103 hasConceptScore W4283778103C2780259306 @default.
• W4283778103 hasConceptScore W4283778103C2780456651 @default.
• W4283778103 hasConceptScore W4283778103C2781182431 @default.
• W4283778103 hasConceptScore W4283778103C31760486 @default.
• W4283778103 hasConceptScore W4283778103C44249647 @default.
• W4283778103 hasConceptScore W4283778103C50382708 @default.
• W4283778103 hasConceptScore W4283778103C526805850 @default.
• W4283778103 hasConceptScore W4283778103C71924100 @default.
• W4283778103 hasConceptScore W4283778103C90924648 @default.
• W4283778103 hasLocation W42837781031 @default.
• W4283778103 hasOpenAccess W4283778103 @default.
• W4283778103 hasPrimaryLocation W42837781031 @default.
• W4283778103 hasRelatedWork W1970564121 @default.
• W4283778103 hasRelatedWork W1991412268 @default.
• W4283778103 hasRelatedWork W2011990520 @default.
• W4283778103 hasRelatedWork W2012954058 @default.
• W4283778103 hasRelatedWork W2182918865 @default.
• W4283778103 hasRelatedWork W2477222816 @default.

• next